|
FDA Advisory Panel to Weigh Use of Animal Studies to Support Approval of Anti-Anthrax Drug
An FDA advisory panel is meeting Friday to make a recommendation on GlaxoSmithKline’s (GSK) anti-anthrax drug raxibacumab.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives